Conceptio › Archive › HAL (France)
HAL (France)open access

Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trial

X. Hu et al.
HAL (France) · Papers · License: Open Access
Open Source ↗
patient-reported-outcomesquality-of-life
HER2-low, Quality of life, Patient-reported outcomes, Metastatic breast cancer, 1, 0, Trastuzumab deruxtecan
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 1066342
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.